The prostate cancer intervention versus observation trial: VA/NCI/AHRQ cooperative studies program #407 (PIVOT): Design and baseline results of a randomized controlled trial comparing radical prostatectomy with watchful waiting for men with clinically localized prostate cancer

Journal of the National Cancer Institute - Monographs

Volumn , Issue 45, 2012, Pages 184-190

  Wilt, Timothy J ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AFRICAN AMERICAN; AGED; ARTICLE; CANCER LOCALIZATION; CANCER MORTALITY; CANCER PATIENT; CANCER RISK; CLINICAL OBSERVATION; COMORBIDITY; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE SEVERITY; ETHNIC DIFFERENCE; GLEASON SCORE; HEALTH PROGRAM; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PATIENT SELECTION; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; RISK FACTOR; SCANDINAVIA; UNITED STATES; WATCHFUL WAITING; BLOOD; CANCER GRADING; CONTROLLED CLINICAL TRIAL; DISEASE COURSE; MIDDLE AGED; NEEDLE BIOPSY; PATHOLOGY; PROSTATE; PROSTATE TUMOR; TREATMENT OUTCOME;

ADULT; AGED; BIOPSY, NEEDLE; DISEASE PROGRESSION; HUMANS; MALE; MIDDLE AGED; NEOPLASM GRADING; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; TREATMENT OUTCOME; WATCHFUL WAITING;

EID: 84871779908     PISSN: 10526773     EISSN: 17456614     Source Type: Book Series    
DOI: 10.1093/jncimonographs/lgs041     Document Type: Article

References (17)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62(1):10-29.
2. Healthcare cost and utilization project (US). Agency for Healthcare Research and Quality Web site. http://www.ahrq.gov/data/hcup/. Accessed December 2006.
3. Wilt TJ, MacDonald R, Rutks I, Shamliyan TA, Taylor BC, Kane RL. Systematic review: comparative effectiveness and harms of treatments for clinically localized prostate cancer. Ann Intern Med. 2008;148(6):435-448.
4. Thompson I, Thrasher JB, Aus G, et al. Guideline for the management of clinically localized prostate cancer: 2007 update. American Urological Association Education and Research Web site: http://www.auanet.org/ content/guidelines-and-quality-care/clinical-guidelines/main-reports/ proscan07/content.pdf. Accessed October 17, 2012.
5. Graham J, Baker M, Macbeth F, Titshall V; Guideline Development Group. Diagnosis and treatment of prostate cancer: summary of NICE guidance. BMJ. 2008;336(7644):610-612.
6. Iversen P, Madsen PO, Corle DK. Radical prostatectomy versus expectant treatment for early carcinoma of the prostate. Twenty-three year follow-up of a prospective randomized study. Scand J Urol Nephrol Suppl. 1995;172:65-72.
7. Bill-Axelson A, Holmberg L, Ruutu M, et al; SPCG-4 Investigators. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med. 2011;364(18):1708-1717.
8. Paulson DF, Lin GH, Hinshaw W, Stephani S. Radical surgery versus radiotherapy for adenocarcinoma of the prostate. J Urol. 1982;128(3):502-504.
9. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373-383.
10. D'Amico AV, Manola J, Loffredo M, Renshaw AA, DellaCroce A, Kantoff PW. 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial. JAMA. 2004;292(7):821-827.
11. Steineck G, Helgesen F, Adolfsson J, et al; Scandinavian Prostatic Cancer Group Study Number 4. Quality of life after radical prostatectomy or watchful waiting. N Engl J Med. 2002;347(11):790-796.
12. Hoffman RM, Hunt WC, Gilliland FD, Stephenson RA, Potosky AL. Patient satisfaction with treatment decisions for clinically localized prostate carcinoma. Results from the Prostate Cancer Outcomes Study. Cancer. 2003;97(7):1653-1662.
13. Freedland SJ, Amling CL, Dorey F, et al; Shared Equal Access Regional Cancer Hospital Database Study Group. Race as an outcome predictor after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database. Urology. 2002;60(4):670-674.
14. Greene KL, Cowan JE, Cooperberg MR, Meng MV, DuChane J, Carroll PR; Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE) Investigators. Who is the average patient presenting with prostate cancer? Urology. 2005;66(5 suppl):76-82.
15. Donovan JL, Peters TJ, Noble S, et al; ProtecT Study Group. Who can best recruit to randomized trials? Randomized trial comparing surgeons and nurses recruiting patients to a trial of treatments for localized prostate cancer (the ProtecT study). J Clin Epidemiol. 2003;56(7):605-609.
16. Ford JG, Howerton MW, Lai GY, et al. Barriers to recruiting underrepresented populations to cancer clinical trials: a systematic review. Cancer. 2008;112(2):228-242.
17. Wilt TJ, Brawer MK, Barry MJ, et al. The Prostate cancer Intervention Versus Observation Trial:VA/NCI/AHRQ Cooperative Studies Program #407 (PIVOT): design and baseline results of a randomized controlled trial comparing radical prostatectomy to watchful waiting for men with clinically localized prostate cancer. Contemp Clin Trials. 2009;30(1): 81-87.